quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:00·52d
PRRelease
ACADIA Pharmaceuticals Inc. logo

Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

ACAD· ACADIA Pharmaceuticals Inc.
Health Care
Original source

Companies

  • ACAD
    ACADIA Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 25UpdateBofA Securities$29.00
  • Feb 24UpdateWolfe Research$33.00
  • Feb 23UpdateMizuho$35.00
  • Oct 21UpdateCitigroup$33.00
  • May 21UpdateDeutsche Bank$35.00
  • Feb 11UpdateDeutsche Bank$22.00

Related

  • PR6d
    Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
  • PR8d
    Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
  • INSIDER16d
    SEC Form 4 filed by Schneyer Mark C.
  • INSIDER16d
    SEC Form 4 filed by Kihara James
  • PR16d
    Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
  • INSIDER28d
    SEC Form 4 filed by Thompson Elizabeth H.Z.
  • INSIDER28d
    SEC Form 4 filed by Rhodes Jennifer J
  • INSIDER28d
    SEC Form 4 filed by Owen Adams Catherine
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022